-
Advertorial
-
FOCUS
-
Guide
-
Lifestyle
-
Tech and Vogue
-
TechandScience
-
CHTF Special
-
Nanshan
-
Futian Today
-
Hit Bravo
-
Special Report
-
Junior Journalist Program
-
World Economy
-
Opinion
-
Diversions
-
Hotels
-
Movies
-
People
-
Person of the week
-
Weekend
-
Photo Highlights
-
Currency Focus
-
Kaleidoscope
-
Tech and Science
-
News Picks
-
Yes Teens
-
Budding Writers
-
Fun
-
Campus
-
Glamour
-
News
-
Digital Paper
-
Food drink
-
Majors_Forum
-
Speak Shenzhen
-
Shopping
-
Business_Markets
-
Restaurants
-
Travel
-
Investment
-
Hotels
-
Yearend Review
-
World
-
Sports
-
Entertainment
-
QINGDAO TODAY
-
In depth
-
Leisure Highlights
-
Markets
-
Business
-
Culture
-
China
-
Shenzhen
-
Important news
在线翻译:
szdaily -> China -> 
Country lowers prices of fourteen cancer drugs
    2018-08-13  08:53    Shenzhen Daily

THE State Medical Insurance Administration has lowered the procurement prices of 14 cancer drugs, asking provincial-level drug procurement platforms to follow the new standard by the end of September.

The National Healthcare Security Administration said Saturday patients are expected to be able to buy these drugs in September.

The decision was based on a recent circular on the adjustment of medical insurance reimbursement and procurement prices of cancer drugs.

The administration will further its guidance to make sure the new prices are implemented, in order to allow the public to enjoy the benefits as soon as possible, a source from the administration said.

Negotiations have been under way between the administration and pharmaceutical companies to add more affordable cancer drugs to the country’s medical insurance reimbursement list.

A range of drugs have been selected, with the administration confirming the producers’ willingness to further negotiate. The drugs are all crucial in dealing with hematological neoplasms and solid tumors, and have great clinical value and bode huge benefits to patients, the administration said.

Negotiations launched in 2017 had lowered the prices of 15 clinically-effective yet highly-priced cancer drugs such as Heceptin, Rituximab, and Bortezomib, as well as added them to the medical insurance reimbursement list.

(Xinhua)

深圳报业集团版权所有, 未经授权禁止复制; Copyright 2010, All Rights Reserved.
Shenzhen Daily E-mail:szdaily@szszd.com.cn